European Commission grants marketing authorization for Revolution Medicines’ RASONQUE in the EU

The European Commission has approved RASONQUE, Revolution Medicines’ oral RAS inhibitor, for use in adults with metastatic pancreatic cancer who have received at least one previous systemic treatment. The authorization applies to all EU member states and the European Economic Area, excluding the United Kingdom and Switzerland. Access timing will depend on each country’s pricing and reimbursement decisions. The approval is based on the Phase 3 RASolute 302 trial, which met its primary and key secondary endpoints.

The approval expands the drug’s market to the EU and EEA, potentially increasing Revolution Medicines’ sales outside the United States. However, actual patient availability will vary by country as national health‑technology assessments and pricing negotiations are completed.

  • 1The European Commission authorized RASONQUE for adult patients with metastatic pancreatic cancer who have had at least one prior systemic therapy.
  • 2The authorization covers all EU member states and EEA countries (Iceland, Norway, Liechtenstein) but not the United Kingdom or Switzerland.
  • 3The decision follows a positive opinion from the EMA’s CHMP and an expedited review under the Cancer Medicines Pathfinder project.
  • 4Approval is based on the Phase 3 RASolute 302 trial, which met all primary and key secondary endpoints in both the overall and RAS‑mutant populations.
  • 5Revolution Medicines said it will work with national reimbursement bodies, and patient access timing will vary by country.
  • 6RVMD shares closed at $166.87, down 3.15% after the announcement.

Sources